150 related articles for article (PubMed ID: 7323811)
1. The Cancer Therapy Evaluation Program of the National Cancer Institute.
Muggia FM; Carter SK; Macdonald JS
Semin Oncol; 1981 Dec; 8(4):394-402. PubMed ID: 7323811
[No Abstract] [Full Text] [Related]
2. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
3. Clinical trials: a recent emphasis in the prevention program of the National Cancer Institute.
DeWys WD; Greenwald P
Semin Oncol; 1983 Sep; 10(3):360-4. PubMed ID: 6665563
[No Abstract] [Full Text] [Related]
4. FDA seeks swifter approval of drugs for some life-threatening or debilitating diseases.
Marwick C
JAMA; 1988 Nov; 260(20):2976. PubMed ID: 3184360
[No Abstract] [Full Text] [Related]
5. Natural product drug discovery and development: the United States National Cancer Institute role.
Cragg GM
P R Health Sci J; 2002 Jun; 21(2):97-111. PubMed ID: 12166031
[No Abstract] [Full Text] [Related]
6. Proceedings of the National Conference on Clinical Trials Methodology.
Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):629-766. PubMed ID: 35299
[No Abstract] [Full Text] [Related]
7. The evaluation of cytotoxic drugs.
Von Hoff DD; Rozencweig M; Muggia FM
Cancer Treat Rev; 1979 Jun; 6 Suppl():1-8. PubMed ID: 498161
[No Abstract] [Full Text] [Related]
8. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
9. Investigational trials of anticancer drugs: establishing safeguards for experimentation.
Chabner BA; Wittes R; Hoth D; Hubbard S
Public Health Rep; 1984; 99(4):355-60. PubMed ID: 6431482
[TBL] [Abstract][Full Text] [Related]
10. FR-901228 Fujisawa/National Cancer Institute.
Vigushin DM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1396-402. PubMed ID: 12498018
[TBL] [Abstract][Full Text] [Related]
11. The National Cancer Chemotherapy Program.
Frei E
Science; 1982 Aug; 217(4560):600-6. PubMed ID: 7046055
[TBL] [Abstract][Full Text] [Related]
12. NCI's cancer therapy evaluation program: a commitment to treatment trials.
Abrams JS; Murgo A; Christian MC
Cancer Treat Res; 2007; 132():31-50. PubMed ID: 17305016
[No Abstract] [Full Text] [Related]
13. Laetrile.
N Engl J Med; 1982 Jul; 307(2):118-20. PubMed ID: 7045657
[No Abstract] [Full Text] [Related]
14. Annual meeting of the New Clinical Drug Evaluation Units (NCDEU) program, Psychopharmacology Research Branch, National Institute of Mental Health, 23-25 May 1978, Key Biscayne, Florida.
Psychopharmacol Bull; 1979 Jul; 15(3):22-44. PubMed ID: 493456
[No Abstract] [Full Text] [Related]
15. Executive summary from the final reports of the National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS.
Oncology (Williston Park); 1991 Apr; 5(4):16, 18-9. PubMed ID: 1831034
[No Abstract] [Full Text] [Related]
16. NCI plans clinical test of laetrile.
Stone B
Am Med News; 1978 Oct; 21(39):1, 11. PubMed ID: 10324743
[No Abstract] [Full Text] [Related]
17. National Cancer Institute begins laetril clinical trial.
JAMA; 1980 Aug; 244(6):538. PubMed ID: 6993703
[No Abstract] [Full Text] [Related]
18. Cancer prevention and control within the National Cancer Institute's clinical trials network: lessons from the Community Clinical Oncology Program.
Kaluzny AD; Warnecke RB; Lacey LM; Morrissey JP; Gillings D; Ozer H
J Natl Cancer Inst; 1993 Nov; 85(22):1807-11. PubMed ID: 8230260
[No Abstract] [Full Text] [Related]
19. Historical and methodological developments in clinical trials at the National Cancer Institute.
Gehan EA; Schneiderman MA
Stat Med; 1990 Aug; 9(8):871-80; discussion 903-6. PubMed ID: 2218190
[TBL] [Abstract][Full Text] [Related]
20. Update on the National Cancer Institute's clinical trials cooperative group program.
Wallner PE
J Am Coll Radiol; 2004 Nov; 1(11):865-6. PubMed ID: 17411719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
